<DOC>
	<DOCNO>NCT02725580</DOCNO>
	<brief_summary>The propose clinical trial first human , open-label , single dose study self-complementary AAV9 carry CLN6 gene deliver one-time intrathecally insert lumbar puncture Batten CLN6 Disease subject . One cohort patient Batten CLN6 Disease , confirm diagnosis , undergo gene transfer . A minimum six patient enrolled cohort .</brief_summary>
	<brief_title>Batten CLN6 Gene Therapy</brief_title>
	<detailed_description>The propose clinical trial first human , open-label , single dose study self-complementary AAV9 carry CLN6 gene control hybrid CMV enhancer/chicken-β-actin promoter ( scAAV9.CB.CLN6 ) deliver one-time intrathecal catheter insert lumbar puncture interspinous subarachnoid space lumbar thecal sac . All six patient receive dose equivalent ( 1.5 x10^13 vg/kg ) . This administer premixed 2.5 mL contrast Omnipaque™ concentration 180 mgI/mL contrast via 10 mL syringe Spinal Needle . If clinically significant improvement without toxicity observe , possibility add additional escalation cohort high dose discuss FDA , DSMB relevant oversight regulatory agency .</detailed_description>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<criteria>Diagnosis CLN6 disease determine genotype available sScreening Quantitative clinical assessment Hamburg motorlanguage aggregate score Screening CLN2 disease motorlanguage scale , define Ratings Assessment Guideline . Age ≥1 year Written inform consent parent legal guardian assent subject , appropriate . Ability comply protocol require assessment ( laboratory sample collection , EEG , ECG , MRI , etc . Another inherited neurologic disease , e.g. , form CLN seizure unrelated CLN2 disease ( patient febrile seizure may eligible ) Another neurological illness may cause cognitive decline ( e.g. , trauma , meningitis , hemorrhage ) screen Active viral infection Has receive stem cell bone marrow transplantation CLN6 disease Contraindications spinal tap procedure ( e.g. , spina bifida , meningitis , impairment , clot abnormality ) Contraindications MRI scan ( e.g. , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) Episode generalize motor status epilepticus within 4 week First Dose visit Severe infection ( e.g. , pneumonia , pyelonephritis , meningitis ) within 4 week First Dose visit ( enrollment may postpone ) Has receive investigational medication within 30 day first infusion study drug Patients AntiAAV9 antibody titer ≥ 1:1600 determined ELISA bind immunoassay . Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol require testing procedure compromise subject 's wellbeing , safety , clinical interpretability Pregnancy time study ; female subject judge investigator childbearing potential tested pregnancy Abnormal laboratory value consider clinically significant ( GGT &gt; 3XULN , Bilirubin ≥ 3.0 mg/dL , Creatinine ≥ 1.8 mg/dL , Hgb &lt; 8 &gt; 18 g/Dl ; WBC &gt; 15,000 per cmm )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuronal ceroid lipofuscinosis</keyword>
	<keyword>NCL</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Gray Foundation</keyword>
</DOC>